近年来，在外源单核细胞/巨噬细胞为基础的治疗策略用于治疗炎症和退行性疾病方面取得了进展。
Recent progress on developing exogenous monocyte/macrophage-based therapies for inflammatory and degenerative diseases.
机构信息
Arthritis Program, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada.
Arthritis Program, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Cell Therapy Program, University Health Network, Toronto, Ontario, Canada; Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
出版信息
Cytotherapy. 2019 Apr;21(4):393-415. doi: 10.1016/j.jcyt.2019.02.002. Epub 2019 Mar 12.
Cell-based therapies are a rapidly developing area of regenerative medicine as dynamic treatments that execute therapeutic functions multimodally. Monocytes and macrophages, as innate immune cells that control inflammation and tissue repair, are increasing popular clinical candidates due to their spectrum of functionality. In this article, we review the role of monocytes and macrophages specifically in inflammatory and degenerative disease pathology and the evidence supporting the use of these cells as an effective therapeutic strategy. We compare current strategies of exogenously polarized monocyte/macrophage therapies regarding dosage, delivery and processing to identify outcomes, advances and challenges to their clinical use. Monocytes/macrophages hold the potential to be a promising therapeutic avenue but understanding and optimization of disease-specific efficacy is needed to accelerate their clinical use.
细胞疗法是再生医学中一个迅速发展的领域，作为一种多模式执行治疗功能的动态治疗方法。单核细胞和巨噬细胞作为控制炎症和组织修复的先天免疫细胞，由于其功能谱而成为越来越受欢迎的临床候选物。在本文中，我们特别回顾了单核细胞和巨噬细胞在炎症和退行性疾病病理学中的作用，以及支持将这些细胞用作有效治疗策略的证据。我们比较了目前外源性极化单核细胞/巨噬细胞治疗的策略，包括剂量、给药和处理，以确定其临床应用的结果、进展和挑战。单核细胞/巨噬细胞有可能成为一种有前途的治疗途径，但需要了解和优化针对特定疾病的疗效，以加速其临床应用。
Zotero 插件